Life sciences pumping more cash than ever into R&D, but drug pricing limits could stymie that tide: report

As a Democrat-led U.S. government is looking to once again up the pressure on drug pricing, a new report has shown biopharmas are in fact reinvesting more and more sales revenue into R&D.

This is according to a new report out from the Congressional Budget Office (CBO) that shows in 2019, the pharma industry spent $83 billion dollars on R&D: When adjusted for inflation, that amount is about 10 times what the industry spent per year in the 1980s. In the last decade, U.S. approvals for new meds have also more than doubled.